DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of "Moderate Buy" from Analysts

DBV Technologies S.A. (NASDAQ:DBVT - Get Free Report) has earned an average rating of "Moderate Buy" from the four ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and three have given a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $14.75.

DBVT has been the topic of several research analyst reports. Lifesci Capital raised DBV Technologies to a "strong-buy" rating in a report on Thursday. Wall Street Zen upgraded DBV Technologies from a "sell" rating to a "hold" rating in a research report on Friday, May 9th. Citigroup reissued an "outperform" rating on shares of DBV Technologies in a report on Tuesday, May 27th. JMP Securities restated a "market outperform" rating and set a $21.00 price objective on shares of DBV Technologies in a research report on Thursday. Finally, HC Wainwright lifted their target price on shares of DBV Technologies from $7.00 to $16.00 and gave the company a "buy" rating in a research report on Monday, May 5th.

Institutional Trading of DBV Technologies

A hedge fund recently bought a new stake in DBV Technologies stock. Boxer Capital Management LLC bought a new stake in DBV Technologies S.A. (NASDAQ:DBVT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 50,000 shares of the company's stock, valued at approximately $154,000. Boxer Capital Management LLC owned 0.24% of DBV Technologies as of its most recent SEC filing. Institutional investors and hedge funds own 71.74% of the company's stock.

DBV Technologies Trading Up 6.6%

Shares of DBVT stock opened at $9.21 on Friday. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $12.78. The stock has a market cap of $252.26 million, a P/E ratio of -1.87 and a beta of -0.63. The stock has a 50 day moving average of $9.22 and a 200 day moving average of $6.24.

DBV Technologies (NASDAQ:DBVT - Get Free Report) last announced its quarterly earnings results on Friday, April 11th. The company reported ($1.10) earnings per share (EPS) for the quarter. The firm had revenue of $0.51 million for the quarter. DBV Technologies had a negative return on equity of 278.24% and a negative net margin of 3,249.99%. On average, research analysts predict that DBV Technologies will post -7.05 earnings per share for the current fiscal year.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.